Navigation Links
Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
Date:1/7/2008

-First Combination Study of a MET and EGFR Inhibitor-

SOUTH SAN FRANCISCO, Calif., Jan. 7 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today announced that it has initiated a phase 1/2 trial of XL184 in patients with non-small cell lung cancer (NSCLC) who have had progressive disease while on a regimen containing erlotinib.

XL184 is a small molecule that simultaneously inhibits the MET, RET and VEGFR receptor tyrosine kinases. In the initial phase 1 part of the study, safety and pharmacokinetics of combining XL184 with erlotinib will be evaluated. The primary endpoint of the phase 2 part of the study is overall response rate. Secondary endpoints include progression-free survival, overall survival and pharmacodynamics.

"XL184 is a potent inhibitor of MET, and MET amplification has been shown to play an important role in the development of resistance to EGFR inhibitors in NSCLC," said Michael Morrissey, Ph.D., president of research and development of Exelixis. "Our preclinical data suggest that XL184 effectively inhibits growth of cancer cells that have become resistant to EGFR inhibitors through activation of the MET signaling pathway. XL184 also potently inhibits VEGFR, which is a validated target in the treatment of NSCLC. The compound has shown encouraging anti-tumor activity in an initial phase 1 trial and we are executing a phase 2 clinical development program, and are planning on initiation of a pivotal trial for XL184 in medullary thyroid cancer in 2008."

The phase 1/2 study of XL184 is expected to enroll up to 86 NSCLC patients who have had disease progression while on erlotinib. The phase 1 portion of the study will evaluate dose escalation of XL184 in combination with erlotinib, both
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
2. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
3. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
4. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
5. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
6. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
7. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
8. GlaxoSmithKline Accelerates Review of Exelixis XL880
9. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
10. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
11. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
(Date:1/15/2014)... 15, 2014  In an unprecedented effort to curb the spread of ... other transport vehicles, an advanced and portable UV germicidal lamp manufactured ... first time. In order to prevent EMS paramedics ... West Palm Beach Fire Rescue is the ...
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... April 28, 2011 The U.S. Food and ... combination with prednisone (a steroid) to treat patients ... received prior docetaxel (chemotherapy). (Logo: ... male sex hormone testosterone stimulates prostate tumors to ...
... -- When running a company, school or hotel, we ... which presents us with everything completely and obviously. It ... need exact test data to diagnose properly. Shenzhen Wuzhou ... of equipment for sale including digital and infrared ...
Cached Medicine Technology:FDA Approves Zytiga for Late-Stage Prostate Cancer 2FDA Approves Zytiga for Late-Stage Prostate Cancer 3Testing With Data to Get a More Convenient Diagnosis 2
(Date:7/10/2014)... tumor cells captured with a microchip-based device developed at ... Medicine and the MGH Cancer Center can be cultured ... testing. In the July 11 issue of ... cultured cells accurately reflect a tumor,s genetic mutation over ... "We now can culture cells from the blood that ...
(Date:7/10/2014)... looking to bump up their grade point averages during ... in a library or study hall, but in a ... students who were members of the recreational sports and ... sophomore years had higher GPAs than those who weren,t. ... memberships stayed in school longer. An increase of 3.5 ...
(Date:7/10/2014)... (July 10, 2014) A research review identifying the ... important first step in the process of developing evidence-based ... a new report published by Neurosurgery ... Neurological Surgeons . The journal is published by ... Wolters Kluwer Health . , Based on ...
(Date:7/10/2014)... as tempting as full-fat equivalents could be heading ... how proteins can replace fats without affecting foodstuffs, ... Engineering and Physical Sciences Research Council (EPSRC), a ... Edinburgh has produced modified proteins that easily break ... behaviour of fats during food manufacture. The proteins ...
(Date:7/9/2014)... researchers reveal that sudden, acute episodes of low back ... temperature, humidity, air pressure, wind direction and precipitation. Findings ... journal of the American College of Rheumatology (ACR), indicate ... with higher wind speed or wind gusts, but was ... Health Organization (WHO) nearly everyone experiences low back pain ...
Breaking Medicine News(10 mins):Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 2Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 3Health News:Want a higher GPA in college? Join a gym 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:Low back pain? Don't blame the weather 2
... LIVERMORE, Calif. , Feb. 1 The ... recently featured headline stories about a clinical study that is ... surprised by the attention this study is getting from the ... Officer of Halt Medical, Inc., a medical technology company headquartered ...
... could lead to false positives -- adding stress to ... unnecessary follow-up treatment and dietary restrictions. But the ... risk of mental retardation, disability or death outweigh the ... research published today in the February issue of the ...
... ... Santen Inc., as its 2010 president. , ... San Francisco (Vocus) -- Ophthalmic Women Leaders (OWL) has appointed ... , , ,Prior to her appointment as president, Gleeson previously served as chair of ...
... , ... solution to overcome the obstacle of health insurance. , ... (PRWEB) February 1, 2010 -- EasyToInsureME announces a new solution to ... are very afraid. This past week states like Virginia and Pennsylvania are already making laws ...
... A ... ... A report on pedestrian accident statistics released by Elmhurst Hospital Center shows that the number of ... report is being analyzed by New York personal injury attorneys to help their clients., ...
... , Feb. 10 Event With Celebrity Panel To Discuss ... The increased scrutiny of the fashion industry and its use of ultrathin ... say that the fashion industry is at least partially responsible for "girls, ... the Girl Scouts of the USA . , The nationwide survey, ...
Cached Medicine News:Health News:Benefits outweigh risks associated with newborn screening for disorder 2Health News:Ophthalmic Women Leaders (OWL) Names Pamela Gleeson, CFO Of Santen Inc., as 2010 President 2Health News:Recent Shoppers Face Health Insurance Obstacles 2Health News:Recent Shoppers Face Health Insurance Obstacles 3Health News:No Surprise to David Perecman And Other Personal Injury Attorneys, Vehicles Lead All Causes of Injury at New York Hospital 2Health News:No Surprise to David Perecman And Other Personal Injury Attorneys, Vehicles Lead All Causes of Injury at New York Hospital 3Health News:Nationwide Study Finds That Teenage Girls Have Mixed Feelings About the Fashion Industry 2Health News:Nationwide Study Finds That Teenage Girls Have Mixed Feelings About the Fashion Industry 3Health News:Nationwide Study Finds That Teenage Girls Have Mixed Feelings About the Fashion Industry 4
... the qualitative differential detection ... antigen and an antigen that ... species of malaria:plasmodium falciparum (P.f), ... (P.o) and Plasmodium malariae (P.m) ...
For the qualitative detection of antibodies to Treponema pallidum in human serum, plasma and whole blood specimens...
For the qualitative detection of antibodies to HIV-1 and HIV-2 in human serum, plasma and whole blood specimens...
... Philips EP navigator is a new ... confirm the position of any catheter ... detailed 3D cardiac anatomy in the ... help you carry out complex EP ...
Medicine Products: